Published in J Virol on September 01, 1975
In vitro synthesis of an infectious RNA from cDNA clones of human rhinovirus type 14. J Virol (1985) 3.19
Picornaviral structure and assembly. Microbiol Rev (1981) 2.93
Determination of the length distribution of poly(A) at the 3' terminus of the virion RNAs of EMC virus, poliovirus, rhinovirus, RAV-61 and CPMV and of mouse globin mRNA. Nucleic Acids Res (1979) 2.02
Polyadenylate sequences of human rhinovirus and poliovirus RNA and cordycepin sensitivity of virus replication. J Virol (1976) 1.01
Effect of cordycepin triphosphate on in vitro RNA synthesis by picornavirus polymerase complexes. J Virol (1978) 0.83
Rhinovirus multistranded RNA: dependence of the replicative form on the presence of actinomycin D. J Virol (1976) 0.75
Purification of biologically active globin messenger RNA by chromatography on oligothymidylic acid-cellulose. Proc Natl Acad Sci U S A (1972) 83.88
A polynucleotide segment rich in adenylic acid in the rapidly-labeled polyribosomal RNA component of mouse sarcoma 180 ascites cells. Proc Natl Acad Sci U S A (1971) 18.25
Purification and properties of the replicative intermediate of the RNA bacteriophage R17. Proc Natl Acad Sci U S A (1966) 7.55
Polyadenylic acid at the 3'-terminus of poliovirus RNA. Proc Natl Acad Sci U S A (1972) 5.42
Addition of polyadenylate sequences to virus-specific RNA during adenovirus replication. Proc Natl Acad Sci U S A (1971) 4.48
Polyadenylic acid sequences in the virion RNA of poliovirus and Eastern Equine Encephalitis virus. Science (1972) 2.78
Sequence studies of poliovirus RNA. III. Polyuridylic acid and polyadenylic acid as components of the purified poliovirus replicative intermediate. J Mol Biol (1975) 2.04
Purification and characterization of poliovirus-induced infectious double-stranded ribonucleic acid. J Biol Chem (1967) 2.00
Poly(C) in animal viral RNAs. Nature (1974) 1.95
Poly(U) in poliovirus minus RNA is 5'-terminal. Biochem Biophys Res Commun (1974) 1.88
Presence of a large poly(rC) tract within the RNA of encephalomyocarditis virus. Nature (1974) 1.83
Poly U tracts absent from viral RNA. Nat New Biol (1972) 1.71
Infectivity and sedimentation of rhinovirus ribonucleic acid. J Virol (1971) 1.29
Presence of poly (A) in the polyribosome-associated RNA of Sindbis-infected BHK cells. Nat New Biol (1972) 1.16
Preliminary observations pertaining to polyadenylation of rhinovirus RNA. J Virol (1974) 1.14
Heterogeneity in the poly(A) content of the genome of Sindbis virus. Virology (1972) 1.04
Purification of mengovirus and identification of an A-rich segment in its ribonucleic acid. J Gen Virol (1972) 1.02
Analysis of poliovirus-specific RNA in infected HeLa cells by polyacrylamide gel electrophoresis. Virology (1969) 0.99
Replication of rhinovirus RNA. J Gen Virol (1973) 0.94
Identification of the sequence responsible for the nuclear accumulation of the influenza virus nucleoprotein in Xenopus oocytes. Cell (1985) 3.36
Dependence of the activity of an influenza virus neuraminidase upon Ca2+. J Gen Virol (1971) 2.59
Differences between the thermal inactivation of picornaviruses at "high" and "low" temperatures. Virology (1967) 2.41
Mechanisms of neutralization of animal viruses. J Gen Virol (1984) 2.16
Coronaviridae: second report. Intervirology (1978) 2.05
Review article initial stages in infection with animal viruses. J Gen Virol (1982) 1.87
Defective interfering viruses and infections of animals. Curr Top Microbiol Immunol (1986) 1.83
Enzyme-linked immunosorbent assay for detection of antibody in volunteers experimentally infected with human coronavirus strain 229 E. J Clin Microbiol (1980) 1.73
An electron microscopic study of single-cycle infection of chick embryo fibroblasts by influenza virus. Virology (1969) 1.65
Identification of a neutralization-specific antigen of a calf rotavirus. J Gen Virol (1982) 1.64
New virus-specific antigens in cells infected with influenza virus. Virology (1969) 1.48
Effect of antibody to neuraminidase on the maturation and hemagglutinating activity of an influenza A2 virus. J Virol (1969) 1.47
Defective interfering viruses and their potential as antiviral agents. Rev Med Virol (2010) 1.44
Coronaviridae. Intervirology (1983) 1.42
Quantitative relationships between an influenza virus and neutralizing antibody. Virology (1987) 1.37
Neutralization of animal virus infectivity by antibody. Arch Virol (2007) 1.34
Mechanism of neutralization of influenza virus by secretory IgA is different from that of monomeric IgA or IgG. J Exp Med (1985) 1.29
Electrophoretic separation of influenza virus ribonucleoproteins. J Gen Virol (1981) 1.27
Neutralization escape mutants of type A influenza virus are readily selected by antisera from mice immunized with whole virus: a possible mechanism for antigenic drift. J Gen Virol (1994) 1.26
Mechanisms of neutralization of influenza virus on mouse tracheal epithelial cells by mouse monoclonal polymeric IgA and polyclonal IgM directed against the viral haemagglutinin. J Gen Virol (1990) 1.24
A human IgG1 (b12) specific for the CD4 binding site of HIV-1 neutralizes by inhibiting the virus fusion entry process, but b12 Fab neutralizes by inhibiting a postfusion event. Virology (1997) 1.24
The genome of human coronavirus strain 229E. J Gen Virol (1978) 1.21
The polypeptide composition of avain infectious bronchitis virus particles. Arch Virol (1977) 1.19
Biophysical studies of a rhinovirus. Extraction and assay of infectious ribonucleic acid. Nature (1966) 1.19
Inhibition of synthesis of influenza virus proteins: evidence of two host-cell-dependent events during multiplication. Virology (1975) 1.19
Ribonucleoprotein of avian infectious bronchitis virus. J Gen Virol (1981) 1.13
Insights into neutralization of animal viruses gained from study of influenza virus. Epidemiol Infect (1991) 1.12
Enzyme-linked immunosorbent assay for coronaviruses HCV 229E and MHV 3. J Gen Virol (1980) 1.10
Antibody to virus components in volunteers experimentally infected with human coronavirus 229E group viruses. Infect Immun (1981) 1.10
Prevention of death in Semliki Forest virus-infected mice by administration of defective-interfering Semliki Forest virus. J Gen Virol (1978) 1.09
The RNAs of defective-interfering influenza virus. Virology (1978) 1.09
The characterisation of the virion RNA of avian infectious bronchitis virus. FEBS Lett (1977) 1.08
Single- and multi-hit kinetics of immunoglobulin G neutralization of human immunodeficiency virus type 1 by monoclonal antibodies. J Gen Virol (1994) 1.08
Studies on the mechanism of neutralization of influenza virus by antibody: evidence that neutralizing antibody (anti-haemagglutinin) inactivates influenza virus in vivo by inhibiting virion transcriptase activity. J Gen Virol (1982) 1.07
Defective segment 1 RNAs that interfere with production of infectious influenza A virus require at least 150 nucleotides of 5' sequence: evidence from a plasmid-driven system. J Gen Virol (2002) 1.06
A haemagglutinin (HA1)-specific FAb neutralizes influenza A virus by inhibiting fusion activity. J Gen Virol (2001) 1.06
Variations in the neutralizing and haemagglutination-inhibiting activities of five influenza A virus-specific IgGs and their antibody fragments. J Gen Virol (1997) 1.05
Hemagglutinin 1-specific immunoglobulin G and Fab molecules mediate postattachment neutralization of influenza A virus by inhibition of an early fusion event. J Virol (2001) 1.04
Approximately 150 nucleotides from the 5' end of an influenza A segment 1 defective virion RNA are needed for genome stability during passage of defective virus in infected cells. Virology (2000) 1.03
Comparison of the morphology of three coronaviruses. Arch Virol (1979) 1.03
Studies on antigenic variations of the haemagglutinin and neuraminidase of swine influenza virus isolates. J Gen Virol (1970) 1.02
Infectivity of human coronavirus strain 229E. J Clin Microbiol (1980) 1.01
Phosphorylation of influenza virus nucleoprotein in vivo. J Gen Virol (1981) 1.01
Failure of an influenza virus to initiate infection in enucleate BHK cells. J Virol (1974) 1.00
Occurrence and frequency of coronavirus infections in humans as determined by enzyme-linked immunosorbent assay. Infect Immun (1982) 0.99
Two particle types of avian infectious bronchitis virus. J Gen Virol (1980) 0.98
Prevalence of human coronavirus antibody in the population of southern Iraq. J Med Virol (1982) 0.98
Morphological studies of the neutralization of influenza virus by IgM. J Gen Virol (1990) 0.98
Human immunodeficiency virus type 1-neutralizing antibodies raised to a glycoprotein 41 peptide expressed on the surface of a plant virus. AIDS Res Hum Retroviruses (1995) 0.98
Early events in influenza virus multiplication. II. Penetration of virus into cells at 4 degrees. Virology (1978) 0.97
Mouse hepatitis virus strain 3 infection of C57, A/Sn and A/J strain mice and their macrophages. Brief report. Arch Virol (1980) 0.97
Fowl plaque virus replication in mammalian cell-avian erythrocyte heterokaryons: studies concerning the actinomycin D and ultra-violet light sensitive phase in influenza virus replication. Virology (1974) 0.96
The polypeptides of human and mouse coronaviruses. Brief report. Arch Virol (1980) 0.96
Semliki Forest virus infection of mice: a model for genetic and molecular analysis of viral pathogenicity. J Gen Virol (1985) 0.95
Protection of mice from lethal influenza by adoptive transfer of non-neutralizing haemagglutination-inhibiting IgG obtained from the lungs of infected animals treated with defective interfering virus. J Gen Virol (1989) 0.95
Summary of antibody workshop: The Role of Humoral Immunity in the Treatment and Prevention of Emerging and Extant Infectious Diseases. J Infect Dis (1997) 0.95
Two antigenic groups of human coronaviruses detected by using enzyme-linked immunosorbent assay. Infect Immun (1981) 0.95
Two neutralizing anti-V3 monoclonal antibodies act by affecting different functions of human immunodeficiency virus type 1. J Gen Virol (1996) 0.94
Replication of rhinovirus RNA. J Gen Virol (1973) 0.94
Selection of neutralizing antibody escape mutants with type A influenza virus HA-specific polyclonal antisera: possible significance for antigenic drift. Epidemiol Infect (1997) 0.94
Categorization of nucleoproteins and matrix proteins from type A influenza viruses by peptide mapping. Virology (1980) 0.94
Interfering vaccine (defective interfering influenza A virus) protects ferrets from influenza, and allows them to develop solid immunity to reinfection. Vaccine (2006) 0.94
Common sequence elements in structurally unrelated genomes of defective interfering Semliki Forest virus. Virology (1994) 0.93
High and low efficiency neutralization epitopes on the haemagglutinin of type A influenza virus. J Gen Virol (1997) 0.93
Location of influenza virus M, NP and NS1 proteins in microinjected cells. J Gen Virol (1985) 0.93
Kinetics of synthesis of influenza virus ribonucleoprotein structures. J Gen Virol (1982) 0.92
Protection of mice from lethal influenza: evidence that defective interfering virus modulates the immune response and not virus multiplication. J Gen Virol (1986) 0.91
Temporal control of transcription of influenza virus RNA. Virology (1975) 0.90
Selective inhibition of influenza virus protein synthesis by inhibitors of DNA function. Virology (1977) 0.90
One defective interfering particle per cell prevents influenza virus-mediated cytopathology: an efficient assay system. J Gen Virol (1988) 0.90
Antigenicity of mouse hepatitis virus strain 3 subcomponents in C57 strain mice. Arch Virol (1981) 0.90
Analysis of the ability of five adjuvants to enhance immune responses to a chimeric plant virus displaying an HIV-1 peptide. Vaccine (1999) 0.89
IgG neutralization of type A influenza viruses and the inhibition of the endosomal fusion stage of the infectious pathway in BHK cells. Virology (1993) 0.89
A monoclonal antibody produced during infection which recognizes an epitope of influenza hemagglutinin only in the context of H-2k MHC class I antigen. J Immunol (1993) 0.88
A rapid method for the inactivation of virus infectivity prior to assay for interferons. J Virol Methods (1984) 0.88
IgG-neutralized influenza virus undergoes primary, but not secondary uncoating in vivo. J Gen Virol (1989) 0.88
Defective interfering particles of Semliki Forest virus are smaller than particles of standard virus. J Gen Virol (1984) 0.87
All rabbits immunized with type A influenza virions have a serum haemagglutination-inhibition antibody response biased to a single epitope in antigenic site B. J Gen Virol (1995) 0.86
Properties of a neutralizing antibody that recognizes a conformational form of epitope ERDRD in the gp41 C-terminal tail of human immunodeficiency virus type 1. J Gen Virol (2000) 0.86
Mechanisms of neutralization of influenza virus by IgM. J Gen Virol (1985) 0.86
Human enteric coronaviruses. Brief review. Arch Virol (1981) 0.85
Determination of affinities of a panel of IgGs and Fabs for whole enveloped (influenza A) virions using surface plasmon resonance. J Virol Methods (1996) 0.85
Rhinovirus RNA polymerase: products and kinetics of appearance in human diploid cells. J Virol (1974) 0.85
Different patterns of polyadenylation of rhinovirus: specified RNA during multiplication in human aneuploid and diploid cells. J Gen Virol (1976) 0.85
Intranasal immunization with a plant virus expressing a peptide from HIV-1 gp41 stimulates better mucosal and systemic HIV-1-specific IgA and IgG than oral immunization. J Immunol Methods (1998) 0.85
Replication of human respiratory coronavirus strain 229E in human macrophages. J Gen Virol (1982) 0.84
The neutralizing antibody response against a conserved region of human immunodeficiency virus type 1 gp41 (amino acid residues 731-752) is uniquely directed against a conformational epitope. J Gen Virol (1998) 0.84
The effect of defective-interfering Semliki Forest virus on the histopathology of infection with virulent Semliki Forest virus in mice. J Infect Dis (1982) 0.84
RNA'S of influenza C virus strains. Arch Virol (1979) 0.84
Early events in influenza virus infection. III. The formation of a nucleoplasmic ribonucleoprotein complex from the input virion. Virology (1978) 0.83
Defective interfering type A equine influenza virus (H3N8) protects mice from morbidity and mortality caused by homologous and heterologous subtypes of influenza A virus. J Gen Virol (1994) 0.83